{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:26:32Z","timestamp":1793499992201,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA214278"],"award-info":[{"award-number":["P01 CA214278"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AG066100"],"award-info":[{"award-number":["U01 AG066100"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016520"],"award-info":[{"award-number":["P30 CA016520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA214278"],"award-info":[{"award-number":["P01 CA214278"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA214278"],"award-info":[{"award-number":["P01 CA214278"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA214278"],"award-info":[{"award-number":["P01 CA214278"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AG066100"],"award-info":[{"award-number":["U01 AG066100"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["Engineering Research Center for Cell Manufacturing Technologies"],"award-info":[{"award-number":["Engineering Research Center for Cell Manufacturing Technologies"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["Engineering Research Center for Cell Manufacturing Technologies"],"award-info":[{"award-number":["Engineering Research Center for Cell Manufacturing Technologies"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000953","name":"Alliance for Cancer Gene Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000953","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001384","name":"Samuel Waxman Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001384","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Parker Institute for Cancer Immunotherapy Innovation Challenge Award Danaher Corporation Chambers Centurion"},{"name":"Parker Institute for Cancer Immunotherapy Innovation Challenge Award"},{"name":"Parker Institute for Cancer Immunotherapy Danaher Corporation Samuel Waxman Cancer Research Foundation Chambers Centurion"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-026-01633-7","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:02:25Z","timestamp":1773050545000},"page":"803-814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4083-5083","authenticated-orcid":false,"given":"Gregory M.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Gering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Satulovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarbani","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Karar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa E.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5115-1321","authenticated-orcid":false,"given":"Julie K.","family":"Jadlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-0194","authenticated-orcid":false,"given":"Luca","family":"Paruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Amses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":false,"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-7778","authenticated-orcid":false,"given":"Saar I.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5494-6128","authenticated-orcid":false,"given":"Kelvin C.","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha I.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Spasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6971-8465","authenticated-orcid":false,"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-2251","authenticated-orcid":false,"given":"Don L.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3265-6878","authenticated-orcid":false,"given":"Angel","family":"Ram\u00edrez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Cabanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EnJun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-4304","authenticated-orcid":false,"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-4056","authenticated-orcid":false,"given":"Frederic D.","family":"Bushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-5771","authenticated-orcid":false,"given":"Zinaida","family":"Good","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-1956","authenticated-orcid":false,"given":"E.","family":"John Wherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-8993","authenticated-orcid":false,"given":"Joseph A.","family":"Fraietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"1633_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1633_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"1633_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"1633_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1633_CR5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1633_CR6","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1633_CR7","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie, C. et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N. Engl. J. Med. 391, 2219\u20132230 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1633_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"1633_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong, E. A., Ruella, M. & Schuster, S. J. & Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N. Engl. J. Med. 384, 673\u2013674 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1633_CR10","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545\u20132554 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1633_CR11","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1200\/JCO.19.03237","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey, N. V. et al. Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia. J. Clin. Oncol. 38, 2862\u20132871 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1633_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.19.01892","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey, N. V. et al. Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J. Clin. Oncol. 38, 415\u2013422 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1633_CR13","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","volume":"373","author":"AL Garfall","year":"2015","unstructured":"Garfall, A. L. et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N. Engl. J. Med. 373, 1040\u20131047 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1633_CR14","doi-asserted-by":"crossref","unstructured":"Garfall, A. L. et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3, e120505 (2018).","DOI":"10.1172\/jci.insight.120505"},{"key":"1633_CR15","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210\u20132221 (2019).","journal-title":"J. Clin. Invest."},{"key":"1633_CR16","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1633_CR17","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","volume":"6","author":"S Gill","year":"2022","unstructured":"Gill, S. et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 6, 5774\u20135785 (2022).","journal-title":"Blood Adv."},{"key":"1633_CR18","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","volume":"27","author":"N Singh","year":"2021","unstructured":"Singh, N. et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat. Med. 27, 842\u2013850 (2021).","journal-title":"Nat. Med."},{"key":"1633_CR19","doi-asserted-by":"publisher","unstructured":"Bhagwat, A. S. et al. Cytokine-mediated CAR T therapy resistance in AML. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03271-5 (2024).","DOI":"10.1038\/s41591-024-03271-5"},{"key":"1633_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"1633_CR21","doi-asserted-by":"crossref","unstructured":"Breiman, L. Random forests. Mach. Learn. 45, 5\u201332 (2001).","DOI":"10.1023\/A:1010933404324"},{"key":"1633_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1214\/09-AOAS285","volume":"4","author":"HA Chipman","year":"2010","unstructured":"Chipman, H. A., George, E. I. & McCulloch, R. E. BART: Bayesian additive regression trees. Ann. Appl. Stat. 4, 266\u2013298 (2010).","journal-title":"Ann. Appl. Stat."},{"key":"1633_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/00401706.1970.10488634","volume":"12","author":"AE Hoerl","year":"1970","unstructured":"Hoerl, A. E. & Kennard, R. W. Ridge regression: biased estimation for nonorthogonal problems. Technometrics 12, 55 (1970).","journal-title":"Technometrics"},{"key":"1633_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. B Stat. Methodol. 58, 267\u2013288 (1996).","journal-title":"J. R. Stat. Soc. B Stat. Methodol."},{"key":"1633_CR25","doi-asserted-by":"publisher","unstructured":"Chen, T. & Guestrin, C. XGBoost. In Proc. 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining https:\/\/doi.org\/10.1145\/2939672.2939785 (ACM, 2016).","DOI":"10.1145\/2939672.2939785"},{"key":"1633_CR26","unstructured":"Rish, I. An empirical study of the naive Bayes classifier. In IJCAI 2001 Workshop on Empirical Methods in Artificial Intelligence 41\u201346 (IJCAI, 2001)."},{"key":"1633_CR27","doi-asserted-by":"publisher","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","volume":"8","author":"N Singh","year":"2016","unstructured":"Singh, N., Perazzelli, J., Grupp, S. A. & Barrett, D. M. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci. Transl. Med. 8, 320ra3 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1633_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41586-023-06816-9","volume":"625","author":"A Cui","year":"2024","unstructured":"Cui, A. et al. Dictionary of immune responses to cytokines at single-cell resolution. Nature 625, 377\u2013384 (2024).","journal-title":"Nature"},{"key":"1633_CR29","doi-asserted-by":"publisher","first-page":"7571","DOI":"10.4049\/jimmunol.166.12.7571","volume":"166","author":"R Salcedo","year":"2001","unstructured":"Salcedo, R. et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J. Immunol. 166, 7571\u20137578 (2001).","journal-title":"J. Immunol."},{"key":"1633_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/sj.cr.7310017","volume":"16","author":"Y Shi","year":"2006","unstructured":"Shi, Y. et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don\u2019t know. Cell Res. 16, 126\u2013133 (2006).","journal-title":"Cell Res."},{"key":"1633_CR31","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.4049\/jimmunol.130.4.1784","volume":"130","author":"T Kasahara","year":"1983","unstructured":"Kasahara, T., Hooks, J. J., Dougherty, S. F. & Oppenheim, J. J. Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J. Immunol. 130, 1784\u20131789 (1983).","journal-title":"J. Immunol."},{"key":"1633_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133\u2013146 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"1633_CR33","doi-asserted-by":"crossref","unstructured":"Hershey, G. K. K. IL-13 receptors and signaling pathways: an evolving web. J. Allergy Clin. Immunol. 111, 677\u2013690 (2003). quiz 691.","DOI":"10.1067\/mai.2003.1333"},{"key":"1633_CR34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/icb.2014.1","volume":"92","author":"ND Huntington","year":"2014","unstructured":"Huntington, N. D. The unconventional expression of IL-15 and its role in NK cell homeostasis. Immunol. Cell Biol. 92, 210\u2013213 (2014).","journal-title":"Immunol. Cell Biol."},{"key":"1633_CR35","first-page":"220","volume":"78","author":"WA Dik","year":"2020","unstructured":"Dik, W. A. & Heron, M. Clinical significance of soluble interleukin-2 receptor measurement in immune-mediated diseases. Neth. J. Med. 78, 220\u2013231 (2020).","journal-title":"Neth. J. Med."},{"key":"1633_CR36","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.4049\/jimmunol.165.7.3620","volume":"165","author":"N Noben-Trauth","year":"2000","unstructured":"Noben-Trauth, N., Hu-Li, J. & Paul, W. E. Conventional, naive CD4+ T cells provide an initial source of IL-4 during Th2 differentiation. J. Immunol. 165, 3620\u20133625 (2000).","journal-title":"J. Immunol."},{"key":"1633_CR37","doi-asserted-by":"publisher","first-page":"S466","DOI":"10.1097\/01.CCM.0000186783.34908.18","volume":"33","author":"DG Remick","year":"2005","unstructured":"Remick, D. G. Interleukin-8. Crit. Care Med. 33, S466\u2013S467 (2005).","journal-title":"Crit. Care Med."},{"key":"1633_CR38","first-page":"121","volume":"22","author":"M Liu","year":"2011","unstructured":"Liu, M. et al. CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 22, 121\u2013130 (2011).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1633_CR39","doi-asserted-by":"publisher","first-page":"722916","DOI":"10.3389\/fonc.2021.722916","volume":"11","author":"J Jin","year":"2021","unstructured":"Jin, J. et al. CCL2: an important mediator between tumor cells and host cells in tumor microenvironment. Front. Oncol. 11, 722916 (2021).","journal-title":"Front. Oncol."},{"key":"1633_CR40","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House, I. G. et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin. Cancer Res. 26, 487\u2013504 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1633_CR41","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1359-6101(02)00045-X","volume":"13","author":"P Menten","year":"2002","unstructured":"Menten, P., Wuyts, A. & Van Damme, J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev. 13, 455\u2013481 (2002).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1633_CR42","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1517\/14728222.2013.837886","volume":"17","author":"RE Marques","year":"2013","unstructured":"Marques, R. E., Guabiraba, R., Russo, R. C. & Teixeira, M. M. Targeting CCL5 in inflammation. Expert Opin. Ther. Targets 17, 1439\u20131460 (2013).","journal-title":"Expert Opin. Ther. Targets"},{"key":"1633_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000289196","volume":"11","author":"JV Falvo","year":"2010","unstructured":"Falvo, J. V., Tsytsykova, A. V. & Goldfeld, A. E. Transcriptional control of the TNF gene. Curr. Dir. Autoimmun. 11, 27\u201360 (2010).","journal-title":"Curr. Dir. Autoimmun."},{"key":"1633_CR44","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1093\/bioinformatics\/btt383","volume":"29","author":"N De Jay","year":"2013","unstructured":"De Jay, N. et al. mRMRe: an R package for parallelized mRMR ensemble feature selection. Bioinformatics 29, 2365\u20132368 (2013).","journal-title":"Bioinformatics"},{"key":"1633_CR45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcancer.2023.02.007","volume":"91","author":"T Li","year":"2023","unstructured":"Li, T. et al. Artificial intelligence in cancer immunotherapy: applications in neoantigen recognition, antibody design and immunotherapy response prediction. Semin. Cancer Biol. 91, 50\u201369 (2023).","journal-title":"Semin. Cancer Biol."},{"key":"1633_CR46","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1016\/j.csbj.2021.07.003","volume":"19","author":"R Rafique","year":"2021","unstructured":"Rafique, R., Islam, S. M. R. & Kazi, J. U. Machine learning in the prediction of cancer therapy. Comput. Struct. Biotechnol. J. 19, 4003\u20134017 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"1633_CR47","doi-asserted-by":"publisher","first-page":"104367","DOI":"10.1016\/j.jbi.2023.104367","volume":"142","author":"A Bogatu","year":"2023","unstructured":"Bogatu, A. et al. Meta-analysis informed machine learning: supporting cytokine storm detection during CAR-T cell Therapy. J. Biomed. Inform. 142, 104367 (2023).","journal-title":"J. Biomed. Inform."},{"key":"1633_CR48","doi-asserted-by":"publisher","unstructured":"Chen, G. M. et al. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1677 (2021).","DOI":"10.1158\/2159-8290.CD-20-1677"},{"key":"1633_CR49","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12859-016-1228-x","volume":"17","author":"BFF Huang","year":"2016","unstructured":"Huang, B. F. F. & Boutros, P. C. The parameter sensitivity of random forests. BMC Bioinformatics 17, 331 (2016).","journal-title":"BMC Bioinformatics"},{"key":"1633_CR50","first-page":"192","volume":"23","author":"RS Olson","year":"2018","unstructured":"Olson, R. S., Cava, W. L., Mustahsan, Z., Varik, A. & Moore, J. H. Data-driven advice for applying machine learning to bioinformatics problems. Pac. Symp. Biocomput. 23, 192\u2013203 (2018).","journal-title":"Pac. Symp. Biocomput."},{"key":"1633_CR51","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nmeth.4438","volume":"14","author":"N Altman","year":"2017","unstructured":"Altman, N. & Krzywinski, M. Ensemble methods: bagging and random forests. Nat. Methods 14, 933\u2013934 (2017).","journal-title":"Nat. Methods"},{"key":"1633_CR52","doi-asserted-by":"crossref","unstructured":"Couronn\u00e9, R., Probst, P. & Boulesteix, A.-L. Random forest versus logistic regression: a large-scale benchmark experiment. BMC Bioinformatics 19, 270 (2018).","DOI":"10.1186\/s12859-018-2264-5"},{"key":"1633_CR53","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664\u2013679 (2016).","journal-title":"Cancer Discov."},{"key":"1633_CR54","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S2589-7500(20)30102-3","volume":"2","author":"CS Lee","year":"2020","unstructured":"Lee, C. S. & Lee, A. Y. Clinical applications of continual learning machine learning. Lancet Digit. Health 2, e279\u2013e281 (2020).","journal-title":"Lancet Digit. Health"},{"key":"1633_CR55","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s42256-022-00568-3","volume":"4","author":"GM van de Ven","year":"2022","unstructured":"van de Ven, G. M., Tuytelaars, T. & Tolias, A. S. Three types of incremental learning. Nat. Mach. Intell. 4, 1185\u20131197 (2022).","journal-title":"Nat. Mach. Intell."},{"key":"1633_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41591-021-01614-0","volume":"28","author":"P Rajpurkar","year":"2022","unstructured":"Rajpurkar, P., Chen, E., Banerjee, O. & Topol, E. J. AI in health and medicine. Nat. Med. 28, 31\u201338 (2022).","journal-title":"Nat. Med."},{"key":"1633_CR57","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453\u20131464 (2009).","journal-title":"Mol. Ther."},{"key":"1633_CR58","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1633_CR59","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1471-2105-10-106","volume":"10","author":"F Hahne","year":"2009","unstructured":"Hahne, F. et al. flowCore: a Bioconductor package for high throughput flow cytometry. BMC Bioinformatics 10, 106 (2009).","journal-title":"BMC Bioinformatics"},{"key":"1633_CR60","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1633_CR61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nbt.4314","volume":"37","author":"E Becht","year":"2018","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38\u201344 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1633_CR62","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/cyto.a.22625","volume":"87","author":"S Van Gassen","year":"2015","unstructured":"Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636\u2013645 (2015).","journal-title":"Cytometry A"},{"key":"1633_CR63","doi-asserted-by":"crossref","unstructured":"Waltman, L. & van Eck, N. J. A smart local moving algorithm for large-scale modularity-based community detection. Eur. Phys. J. B 86, 471 (2013).","DOI":"10.1140\/epjb\/e2013-40829-0"},{"key":"1633_CR64","doi-asserted-by":"publisher","unstructured":"Chen, G. M. & Fraietta, J. A. Code from: Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-hematologic cancer. Zenodo https:\/\/doi.org\/10.5281\/zenodo.16377725 (2025).","DOI":"10.5281\/zenodo.16377725"}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01633-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01633-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01633-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:02:45Z","timestamp":1776808965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01633-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":64,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1633"],"URL":"https:\/\/doi.org\/10.1038\/s41551-026-01633-7","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C. is a co-founder and holds equity in Tmunity Therapeutics (acquired by Kite), and serves as an advisor for BlueWhale Bio. M.R. is an inventor on multiple patents related to T cell immunotherapy for cancer and autoimmune diseases, which are managed by the University of Pennsylvania and licensed or optioned to Vittoria Biotherapeutics and Tmunity (Kite). M.R. serves as a consultant for Guidepoint, Athenaeum, Mosaic, and GLG, and is a member of the advisory boards of Lumicks, Acera, AbClon, Biocartis, and Vittoria Biotherapeutics. In the past 12 months, M.R. has also served as a consultant for AbbVie, ModeX, and Aleta. E.A.S. serves as a consultant for Janssen and BMS, and receives grant funding from Sorrento and AbbVie. N.V.F., D.L.P. and F.D.B. are affiliated with Sana Biotechnology. N.V.F. also holds consultancy roles with Novartis and Syndax Pharmaceuticals and receives funding from Kite Pharma. E.O.H. has consulting or advisory roles with Blueprint Medicines, Cabaletta Bio and the American Board of Internal Medicine Subspecialty Board and receives research funding from Kite and DISC Medicines. D.L.P. serves on advisory boards for the National Marrow Donor Program, and has or had consulting roles with Novartis, BMS, Kite\/Gilead, Poseida, Sana Biotechnology, and Mirror Biologics, holds equity in Genentech, and receives honoraria from the American Society for Transplantation and Cellular Therapy, and Wiley and Sons Publishing. He received research support from Novartis and BMS and has patents and royalties with Novartis, Tmunity. A.D.C. consults for Janssen, GSK, BMS\/Celgene, Genentech\/Roche, Pfizer, Abbvie, Arcellx, Regeneron, Astrazeneca, Kite, Legend, Prothena, Caribou, Novartis, Moderna, and Ichnos, receives research funding from Genentech\/Roche, GSK, and Janssen, and holds patents related to CAR T-cell therapy with Novartis. S.I.G. has stock ownership in Carisma Therapeutics and Interius Biotherapeutics, serves in an advisory role with Asher Bio, and receives research funding from Carisma Therapeutics and Novartis. He also holds patents for CAR T cells targeting acute myeloid leukaemia and for in vivo CAR T cells. A.L.G. consults for BMS, Janssen, Novartis, GSK, Abbvie, Regeneron, Gracell Bio, and Legend, and receives research funding from Novartis, Janssen, Tmunity, and CRISPR therapeutics. He holds patents related to CAR T-cell therapy with Novartis. S.J.S. serves as a consultant for Acerta, Celgene, Genentech, Novartis, and Pharmacyclics, and receives research funding from Celgene, Gilead, Janssen, Merck, Novartis, and Pharmacyclics. He is also a member of scientific advisory committees for Nordic Nanovector and Caribou Biosciences, and holds patents for methods related to treating PML and for combination therapies of CAR and PD-1 inhibitors. B.L.L. serves or recently served as a consultant or advisory board member for Terumo, GSK, Kite, Avectas, Capstan (Chair), Immuneel, Immusoft, In8bio, Ori Biotech, Oxford Biomedica, ThermoFisher Pharma Services, and UTC Therapeutics. He is a co-founder and equity holder in Tmunity Therapeutics (now acquired by Kite) and Capstan Therapeutics (now acquired by Abbvie), and serves on the board of the Alliance for Cancer Gene Therapy. D.L.S. holds founder\u2019s equity and licensed IP in Verismo Therapeutics, Vetigenics, and Chimeric Therapeutics. C.L.M. is a co-founder and equity holder in Link Cell Therapies, CARGO Therapeutics, and GBM NewCo. She also receives research funding from Lyell and Tune and serves as a consultant for CARGO, Link, GBMNewCo, Immatics, and Ensoma. Z.G. is an inventor on two patent applications, holds equity in Boom Capital Ventures, and consults for Mubadala Ventures. E.J.W. is a member of the Parker Institute for Cancer Immunotherapy and serves as an advisor for several companies, including Absci, Arpelos Bioscience, Arsenal Biosciences, Coherus, Danger Bio, IpiNovyx, New Limit, Marengo, Pluto Immunotherapeutics, Prox Biosciences, Related Sciences, Santa Ana Bio, and Synthekine. He is a founder of Arpelos Bioscience, Danger Bio, and Arsenal Biosciences, and holds stock in Coherus. C.H.J. receives royalties from Novartis and Kite, paid to the University of Pennsylvania. He is a scientific co-founder and equity holder in Capstan Therapeutics, Dispatch Biotherapeutics, and Bluewhale Bio, and serves on the board of AC Immune. He holds advisory roles with several companies, including BluesphereBio, Cabaletta, Carisma, Cartography, Cellares, Cellcarta, Celldex, Danaher, Decheng, ImmuneSensor, Kite, Poseida, Verismo, Viracta, and the WIRB-Copernicus Group. F.D.B. is a scientific co-founder of Biocept, has intellectual property licensed to Novartis, and is a consultant for SANA, Poseida, Encoded, and Johnson and Johnson. J.A.F. holds patents and intellectual property related to T-cell-based cancer immunotherapy, with royalties, and receives funding from Tmunity Therapeutics and Danaher Corporation. He also consults for Retro Biosciences and serves on the scientific advisory boards of Cartography Bio, Shennon Biotechnologies, CellFe Biotech, OverT Bio, and Tceleron Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}